Preoperative radiotherapy (preop-RT) has become part of standard practice offered to improve treatment outcomes in patients with rectal cancer[@b1][@b2]. According to the guidelines for colorectal cancer from the National Comprehensive Cancer Network (NCCN), a minimum of twelve lymph nodes (LNs) must be retrieved and examined for accurate staging and the number of metastatic LNs was validated as an independent prognostic factors[@b3][@b4][@b5]. Many factors can influence the number of LNs harvested after rectal cancer resection and it has been shown that preop-RT might reduce the number of LNs retrieved[@b6][@b7]. With the decreased LNs retrieval, the prognostic value of the LN count might also diminish. Increasingly, there is doubt regarding the recommended minimum retrieval of 12 LNs for ypTNM staging[@b8]. There have been some studies of the optimal LNs retrieval cutoff in ypN0 patients, but few studies have focused on ypN(+) patients. One possible method of identifying a reasonable cutoff value that allows the reliable staging of rectal cancer with LNs metastases treated with preop-RT is to analyze patient survival in a large series of patients diagnosed as ypN(+).

The purpose of this study was to assess the impact of the number of LNs examined on survival of rectal cancer patients treated with preop-RT at ypN(+) stage and to determine the optimal number of LNs that should be examined.

Results
=======

Patient Characteristics in SEER database
----------------------------------------

In our 8-year study period, a total of 1,650 with rectal cancer met our selection criteria, including 1,042 male and 608 female. The median patient age was 57 years (IQR 48-66). There were 1,125 patients with ypN1 stage and 525 with ypN2 stage. Patient demographics and pathological features are summarized in [Table 1](#t1){ref-type="table"}. Patients with ypN2 stage had a lower rate of high/moderate grade tumors, a higher proportion of mucinous/signet ring adenocarcinoma, and higher ratios of ypT3/4 tumor stage, which reached the level of significance (p \< 0.001).

Identification of Cutoff points for the minimum number of LNs retrieved in ypN(+) patients in the SEER database
---------------------------------------------------------------------------------------------------------------

X-tile plots were constructed and the maximum χ2 log-rank value of 14.006 (P \< 0.001) was produced, applying 10 as the optimal cutoff value to divide the cohort into high and low risk subsets in terms of rectal cancer cause-specific survival (RCSS) ([Fig. 1](#f1){ref-type="fig"}). To assess the influence of different LN retrieval on RCSS, we analyzed the individual result using different LN number values ranging from 5 to 19. The number below 5 and over 19 weren't analyzed to guarantee sufficient statistical power. The 5-year RCSSs were calculated for patients with N (LNs number) or more nodes and less than N nodes ([Table 2](#t2){ref-type="table"}). The number of LNs retrieved was a prognosis factor only for number ranging from 8 to 16 (except for 13, P value = 0.062).The 5-year RCSS of patients with N or more nodes increased gradually when N ranged from 5 to 9 and the result was roughly the same from 10 to 15 peaking to 65.7% at cutoff 11; but after the number 16, the 5-year RCSS gradually decreased.

Prognostic value of number of LNs retrieved
-------------------------------------------

The number of LNs and other clinicopathological factors, including elderly patients *(P* \< 0.001), black patients (*P* = 0.043), poor and undifferentiated tumor grades (*P* \< 0.001), mucinous and signet-ring cancer (*P* = 0.001), advanced TN stages (*P* \< 0.001), higher negative to positive LNs ratio (*P* \< 0.001), and number of LNs (*P* \< 0.001), were significant risk factors for poor survival according to univariate analysis ([Table 3](#t3){ref-type="table"}). In univariate analysis, age, race, tumor grade, T stage, N stage, higher negative to positive LNs ratio, and LN counts (with an optimal cutoff of 10) were independently and significantly associated with RCSS ([Table 3](#t3){ref-type="table"}), and a higher number of LNs demonstrated a positive effect on survival (hazard ratio \[HR\] 0.744; 95% confidence interval \[CI\] 0.631-0.877, P *\<* 0.001) ([Table 3](#t3){ref-type="table"}).

Subgroup analysis of the effect of LNs retrieved during ypIII stage
-------------------------------------------------------------------

According to the AJCC-7 rectal cancer staging system, patients with LNs metastases were all classified as ypIII stage, which included three subgroups (i.e., ypIIIA, ypIIIB, and ypIIIC). We then further analyzed these three subgroups. Patients with ypTis (n = 5) and ypTx (n = 23) were excluded from this analysis. The results showed that the retrieved LNs (with a cutoff of 10) were significantly associated with 5-year RCSS, according to the univariate analysis in the ypIIIB (χ2 = 22.817, *P* \< 0.001) and ypIIIC subgroups (χ2 = 13.225, *P* *\<* 0.001), but not in the ypIIIA subgroup (χ2 = 0.121, *P* = *0.728)* ([Fig. 2](#f2){ref-type="fig"}, [Table 4](#t4){ref-type="table"} and [5](#t4){ref-type="table"}, [](#t5){ref-type="table"}). The number of LNs retrieved was also validated as an independent survival factor by multivariate Cox regression in the ypIIIB (LNs≥10, HR 0.698, 95% CI 0.552--0.882, *P* = 0.003) and ypIIIC subgroups (LNs≥10, HR 0.718, 95%CI 0.553--0.933,*P* = 0.013) ([Table 4](#t4){ref-type="table"} and [5](#t4){ref-type="table"}, [](#t5){ref-type="table"})

Discussion
==========

The presence of LN metastases in colorectal cancer is well recognized as one of the most important prognostic factors for long-term outcome[@b9][@b10]. The total number of LNs retrieved is fundamental in most pathological staging systems for colorectal cancer, including the American Joint Committee on Cancer (AJCC), modified Dukes and Astler and Coller. Inadequate LN evaluation is associated with worse outcomes in terms of tumor recurrence and patient survival, particularly in patients with stage II colorectal cancer[@b11][@b12][@b13][@b14]. The World Congress of Gastroenterology proposed examining a minimum of 12 LNs to classify stage II colorectal tumors[@b15]. In the USA, the American Joint Committee on Cancer (AJCC), the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) have also recommended examining at least 12 LNs to assign Stage II rectal disease[@b16]. However, debate exists regarding the importance of increased LN harvests in stage III colorectal cancer. Le Voyer *et al.* showed that for colon cancer patients with N1 stage, there was an absolute 23% improvement in the 5-year overall survival if \>40 LNs were analyzed compared with ≤10 LNs (P \< 0.001); and in patients with N2 stage, the 5-year overall survival rates following analysis of \>35 and \<35 LNs were 71% and 51%, respectively (P = 0.002)[@b11]. Vather *et al.* reported that the mean numbers of LNs examined in stage III patients who died or were alive within 5 years was 13.1 vs 14.8, respectively, and this difference was statistically significant (P \< 0.001)[@b17]. Chen *et al.* showed that the median survival times for colon cancer patients with 1--7, 8--14 and ≥15 LN retrieval were 46, 52 and 67 months, respectively (P \< 0.001)[@b18]. However, several studies failed to demonstrate a similar association between survival and LNs harvest in stage III disease[@b13][@b14][@b19][@b20]. Note that our previous study showed that negative LN count, which does not take positive LN into consideration, was an independent prognostic factor for ypIIIB and ypIIIC rectal cancer patients[@b21]. However, the relationship between LN count and RCSS in ypIII rectal cancer has not been fully investigated. In all present guidelines for rectal cancer clinical practice, total LN count is the main concern. Hence, in this study, we mainly focused on the prognostic significance of the total LNs count in patients with rectal cancer treated with preoperative radiotherapy. We first used X-tile to identify 10 as the optimal cutoff value, and then it was confirmed as one of the optimal cutoff numbers in an additional one-by-one cutoff value analysis from 5 to 19. The 5-year RCSS rates of patients with N (cutoff number) or more nodes gradually increased when N ranged from 5 to 9, which suggested that inadequate LN retrieval in LN positive rectal cancer patients may also reflect the failure to remove the involved LNs, particularly in IIIB and IIIC stage patients in our study, thus increasing the risk of local recurrence and distant metastasis. In addition, it may be a marker of poor quality surgical or pathologic care, both of which may cause poor survival. However, a 10 LN cutoff was not an independent prognostic factor in stage IIIA patients. This finding could be explained by the fact that there was a low percentage(3.3%) of T1-T2 patients with more advanced stage than stage IIIA[@b22], therefore, the probability of understaging is significantly low.

The intended purpose of preop-RT is tumor down-staging by decreasing the primary tumor bulk and associated LN metastases. Some authors have demonstrated that neoadjuvant therapy may result in radiation-induced lymphocyte destruction and stromal fibrosis resulting in alterations of the morphology of the LNs, making it difficult to detect them[@b23][@b24]. Recent research has shown that a decreased number of LNs is related to good tumor response. de Campos-Lobato *et al.* have shown that retrieving fewer than 12 LNs in the proctectomy specimen of rectal cancer patients treated with preoperative chemoradiation does not affect their overall survival and may be a marker of greater tumor response and, consequently, decreased LR rate[@b25]. Rullier *et al.* were also unable to identify any relationship between a reduced number of LNs examined and decreased patient survival[@b26]. Habr-Gama *et al.* have demonstrated good disease-free survival rates in patients with a complete absence of LNs in their specimens[@b27]. We also found that with a cutoff of less than 7, the number of LNs retrieved was not a prognostic factor. Decreased LN retrieval might reflect improved response to preop-RT rather than inappropriate or suboptimal surgical resection in this setting. Most previously published articles determined LN cutoffs considering only a single value, while they barely used one-by-one analysis. In our study, we found that if the cutoff value was greater than 16, the 5-year RCSS rate in patients with a greater number of LNs (i.e., more than the cutoff) would decrease gradually, losing its prognosis value after the number 17(P \> 0.05). Several hypotheses could explain this finding. First, the fact that harvesting a higher total number of LNs may result in higher detection rate of metastatic LNs with resultant upstaging of cancer, - a widely accepted concept in surgery; Second, previous study showed that greater LN retrieval could indicate a worse preop-RT response[@b25]. On average, 5 more LNs were retrieved from ypN2 stage patients compared with ypN1 stage patients (15 *VS* 10), and a poorer tumor regression score results in shorter RCSS rates[@b25][@b26][@b27].

This large population-based study has several potential limitations. First, the SEER database does not include information on the administration of chemotherapy. It is possible that additional or concurrent chemotherapy decreases the number of LNs more than preop-RT alone. Second, individual surgeons, pathologists, and other factors may affect LN harvest, but we cannot adjust for these factors. Finally, SEER database also does not report data on preoperative clinical stage, or tumor regression score, so we cannot analyze the relationship between tumor regression score and LNs retrieval in this study.

In conclusion, our analysis of the SEER database revealed that the number of LNs retrieved was a prognostic factor only for numbers ranging from 8 to 16(except for 13) with a maximum χ2 log-rank value of 14.006 at a cutoff of 10. The good tumor response associated with a reduced number of examined LNs may offset the influence of potential under staging with a cutoff of less than 7. Increased LN retrieval (≥17) could indicate worse preop-RT response and poorer RCSS.

Methods
=======

Patient selection in the SEER database
--------------------------------------

Data from the Surveillance Epidemiology and End Results (SEER) Program of the United States National Cancer Institute, release 2015, were utilized for this study. SEER, a population-based cancer registry, collects cancer incidence and survival data from 18 regional population-based registries covering approximately 26% of the US population. The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and TNM staging of colorectal[@b22][@b28], gastric[@b29], esophageal cancer[@b30] and other cancers.

SEER registry patients eligible for this cohort included those with adenocarcinoma, NOS (8150/3), adenocarcinoma in adenomatous polyps (8210/3), villous adenoma (8261/3) or tubulovillous adenoma (8263/3), mucinous adenocarcinoma (8480/3), signet ring cell carcinoma (8490/3) of the rectum diagnosed from 1998 through 2005 and treated with surgical resection. The inclusive study dates were chosen to allow a known treatment sequence of "radiation prior to surgery". The patient age was limited to 18 to 80 years old. Patients diagnosed after 2006 were excluded to ensure adequate follow-up times. Additional exclusion criteria were as follows: no LNs examined pathologically, ypN0 patients, with synchronous distance metastases, and patients who died within 30 postoperative days.

The following information was retrieved from the SEER database: the patient age, sex, race, extension of primary tumor invasion, radiation sequence, total number of LNs examined, number of involved LNs, grade, survival time, and SEER cause-specific death classification. All cases were restaged based on the AJCC-7 staging. The primary endpoint of the study is RCSS which was calculated from the date of diagnosis to the date of cancer specific death. Deaths attributed to the cancer of interest are treated as events and deaths from other causes are treated as censored observation.

Statistical analysis
--------------------

The LNs cutoff points were analyzed using the X-tile program (<http://www.tissuearray.org/rimmlab/>), which identified the cutoff with the minimum P values from log-rank **χ**^**2**^ statistics for the categorical LNs in terms of survival[@b31]. The relationship between various clinical and histological variables and survival was evaluated using the Kaplan-Meier method. Differences between survival curves were tested for statistical significance by using log rank test. The Cox proportional hazard regression model was used to identify the variables that could independently influence survival in preop-RT rectal cancer patients. The Mann-Whitney *U* test was used for continuous variables, and the chi-square test was used for categorical variables. The 5-year RCSS rate was estimated from Kaplan-Meier curves. Deaths attributed to the rectal cancer of interest are treated as events and deaths from other causes are treated as censored observation. Statistical analyses were performed with the statistical software package SPSS (Statistical Package for the Social Sciences) for Windows, version 17 (SPSS Inc, Chicago, IL, USA). Two-sided p values of less than 0.05 were considered to be statistically significant.
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![X-tile analysis of survival data from the SEER registry.\
X-tile analysis was performed using patient data, which were equally divided into training and validation sets, from the SEER registry. X-tile plots of the training sets are shown in the *left panels*, with plots of matched validation sets shown in the *smaller inset*. The optimal cut-point highlighted by the *black circle* in the *left panels* is shown on a histogram of the entire cohort (*middle panels*), and a Kaplan-Meier plot (*right panels*). *P* values were determined using the cutoff point defined in the training set and applying it to the validation set. [Figure 1](#f1){ref-type="fig"} shows the optimal cutoff point for the ypN (+) patients (10, χ2 = 14.006, *P* \< *0.001*).](srep16990-f1){#f1}

![Log-rank tests of rectal cancer cause-specific survival comparing patients with ≥10 lymph nodes with patients who had \<10 nodes for (a) stage ypIIIA: χ2 = 0.121, *P* = 0.728; (b) stage ypIIIB: χ2 = 22.817, *P* \< 0.001; and (c) stage ypIIIC: χ2 = 13.225, *P* \< 0.001.](srep16990-f2){#f2}

###### Characteristics of patients included in the study and make comparison between the ypN1 and ypN2 groups.

  Characteristic                  Total         ypN1          ypN2      P value
  ---------------------------- ------------ ------------- ------------ ---------
  Media foullow up(mo)          64(2--155)   69 (2--155)   54(2--153)   \<0.001
  Sex                                                                    0.412
  male                             1042       718(63.8)    324(61.7)        
  female                           608       407(36.2.)    201 (38.3)       
  Age                           57(20--80)    58(20-80)    56(21--80)    0.059
  Race                                                                   0.725
  White                            1345       921(81.9)    424(80.9)        
  Black                            128         88(7.8)      40(7.6)         
  Other                            177        116(10.3)     61(11.6)        
  Pathological grading                                                  \<0.001
  High/Moderate                    1133       808(71.8)    325(61.9)        
  Poor/Anaplastic                  376        216(19.2)    160(30.5)        
  Unknown                          141        101(9.0)      40(7.6)         
  Histotype                                                             \<0.001
  Adenocarcinoma                   1333       955(85.0)    378(72.3)        
  Mucinous /Signet ring cell       313        168(15.0)    145(27.7)        
  T stage                                                               \<0.001
  Tis                               5          4(0.4)        1(0.2)         
  T1/T2                            228        182(16.2)     46(8.8)         
  T3/4                             1393       920(81.9)    473(90.1)        
  TX                                23         18(1.6)       5(1.0)         
  No. of LNs dissected          12(1--69)     10(1--58)    15(4--69)    \<0.001

###### Univariate analysis of the influence of different total lymph node count on RCSS in ypIII stage rectal cancer patients.

  Total lymph node count    No.    5-year CCS   Log-rank χ^2^   P value[\*](#t2-fn1){ref-type="fn"}
  ------------------------ ------ ------------ --------------- -------------------------------------
  \<5                       250      58.3%          0.810                      0.368
  ≥5                        1400     61.4%                                        
  \<6                       359      56.1%          3.871                      0.049
  ≥6                        1291     62.3%                                        
  \<7                       457      57.8%          2.008                      0.157
  ≥7                        1193     62.1%                                        
  \<8                       593      55.9%          9.609                      0.002
  ≥8                        1057     63.7%                                        
  \<9                       703      56.6%         11.164                      0.001
  ≥9                        947      64.1%                                        
  \<10                      788      56.6%         14.006                     \<0.001
  ≥10                       862      64.8%                                        
  \<11                      902      57.0%         13.492                      0.001
  ≥11                       748      65.7%                                        
  \<12                      991      58.0%          8.515                      0.004
  ≥12                       659      65.4%                                        
  \<13                      1071     59.3%          3.474                      0.062
  ≥13                       579      64.0%                                        
  \<14                      1140     59.4%          4.127                      0.042
  ≥14                       510      64.3%                                        
  \<15                      1192     59.2%          4.771                      0.029
  ≥15                       458      65.3%                                        
  \<16                      1251     59.8%          3.581                      0.058
  ≥16                       399      64.4%                                        
  \<17                      1304     60.4%          2.165                      0.141
  ≥17                       346      62.3%                                        
  \<18                      1355     60.6%          1.058                      0.304
  ≥18                       295      62.6%                                        
  \<19                      1401     60.6%          1.057                      0.304
  ≥19                       249      62.7%                                        

^\*^P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.

###### Univariate and multivariate survival analyses evaluating the number of retrieved LNs influencing RCSS in ypN(+) rectal cancer patients.

  Variable                              Univariate analysis   Multivariate analysis                         
  --------------------------- -------- --------------------- ----------------------- ---------------------- ---------
  Sex                                          0.070                  0.791                                    NI
  Male                         61.1%                                                                             
  Female                       60.7%                                                                             
  Age                                         24.963                 \<0.001                                 \<0.001
  \<60                         64.6%                                                       Reference             
  ≥60                          55.8%                                                  1.439(1.247--1.659)        
  Race                                         6.311                  0.043                                   0.016
  Caucasian                    62.1%                                                       Reference             
  Black                        51.4%                                                  1.404(1.095--1.799)        
  others                       59.1%                                                  1.170 (0.931--1.471)       
  Grade                                       57.252                 \<0.001                                 \<0.001
  High/ Moderate               65.3%                                                       Reference             
  Poor/ Anaplastic             44.7%                                                  1.657(1.412--1.944)        
  Unknown                      68.5%                                                  0.892(0.672--1.184)        
  Histotype                                   10.876                  0.001                                   0.462
  Adenocarcinoma               62.6%                                                       Reference             
  Mucinous/signet ring cell    54.5%                                                  1.069(0.895--1.276)        
  ypT Stage                                   22.284                 \<0.001                                  0.003
  Tis                          60.0%                                                  1.173(0.287--4.792)        
  T1-2                         76..2%                                                      Reference             
  T3-4                         58.4%                                                  1.565(1.238--1.979)        
  Tx                           60.3%                                                  1.397(0.722--2.704)        
  ypN Stage                                   81.663                 \<0.001                                 \<0.001
  ypN1                         67.5%                                                       Reference             
  ypN2                         46.7%                                                  1.638(1.358--1.975)        
  N/P LNs ratio                               90.460                 \<0.001                                  0.001
  ≦2.33                        49.9%                                                       Reference             
  \>2.33                       70.6%                                                  0.735(0.631--0.877)        
  No. of LNs                                  14.006                 \<0.001                                 \<0.001
  \<10                         56.6%                                                       Reference             
  ≥10                          64.8%                                                  0.744(0.631--0.877)        

NI: not included in multivariate survival analysis.

N/P LNs ratio: The ratio of the number of negative lymph nodes to the number of metastatic lymph nodes.

^\*^P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.

###### Univariate and multivariate survival analyses evaluating the number of retrieved LNs influencing RCSS in ypIIIB rectal cancer patients.

  Variable                      5-year RCCS   Univariate analysis   P[\*](#t4-fn1){ref-type="fn"}   Multivariate analysis  
  ---------------------------- ------------- --------------------- ------------------------------- ----------------------- ---------
  Sex                                                0.576                      0.448                                         NI
   Male                            65.8%                                                                                        
   Female                          63.8%                                                                                        
  Age                                               19.534                     \<0.001                                      \<0.001
   \<60                            69.3%                                                                  Reference             
   ≥60                             59.5%                                                             1.500(1.237--1.820)        
  Race                                               6.580                      0.037                                        0.025
   Caucasian                       66.1%                                                                  Reference             
   Black                           51.8%                                                             1.556(1.131--2.141)        
   others                          67.9%                                                             1.025(0.731--1.437)        
  Grade                                             34.685                     \<0.001                                      \<0.001
   High/ Moderate                  69.1%                                                                  Reference             
   Poor/ Anaplastic                47.8%                                                             1.728(1.388-2.151)         
   Unknown                         74.2%                                                             0.803(0.536--1.203)        
  Histotype                                          5.186                      0.023                                        0.325
   Adenocarcinoma                  66.5%                                                                  Reference             
   Mucinous/signet ring cell       58.9%                                                             1.134(0.883--1.455)        
  ypT Stage                                          6.475                      0.039                                        0.009
   T1-2                            53.8%                                                                  Reference             
   T3                              67.6%                                                             0.973(0.460-2.059)         
   T4                              60.5%                                                             1.364(0.625--2.975)        
  ypN Stage                                         13.788                     \<0.001                                       0.002
   ypN1                            67.1%                                                                  Reference             
   ypN2                            53.6%                                                             1.616(1.195--2.185)        
  N/P LNs ratio                                     27.218                     \<0.001                                       0.070
   ≦2.33                           56.1%                                                                  Reference             
   \>2.33                          70.4%                                                             0.801(0.629--1.019)        
  No. of LNs                                        22.817                     \<0.001                                       0.003
   \<10                            58.8%                                                                  Reference             
   ≥10                             72.0%                                                             0.698(0.552--0.882)        

NI: not included in multivariate survival analysis.

N/P LNs ratio: The ratio of the number of negative lymph nodes to the number of metastatic lymph nodes.

^\*^P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.

###### Univariate and Multivariate survival analyses for evaluating the number of LNs retrieved influencing RCSS in ypIIIC rectal cancer patients.

  Variable                      5-year CCS   Univariate analysis   P[\*](#t5-fn1){ref-type="fn"}   Multivariate analysis  
  ---------------------------- ------------ --------------------- ------------------------------- ----------------------- ---------
  Sex                                               0.716                      0.397                                         NI
   Male                           40.5%                                                                                        
   Female                         45.2%                                                                                        
  Age                                               7.615                      0.006                                        0.010
   \<60                           45.0%                                                                  Reference             
   ≥60                            36.6%                                                             1.383(1.082--1.769)        
  Race                                              1.001                      0.606                                         NI
   Caucasian                      42.4%                                                                                        
   Black                          43.0%                                                                                        
   others                         37.6%                                                                                        
  Grade                                             9.790                      0.007                                        0.018
   High/ Moderate                 45.2%                                                                  Reference             
   Poor/Anaplastic                31.4%                                                             1.470(1.126--1.921)        
   Unknown                        50.4%                                                             1.083(0.709--1.654)        
   Histotype                                        0.149                      0.699                                         NI
   Adenocarcinoma                 41.5%                                                                                        
   Mucinous/signet ring cell      43.2%                                                                                        
  ypT Stage                                         4.371                      0.037                                        0.033
   T3                             50.8%                                                                  Reference             
   T4                             39.2%                                                             1.428(1.030--1.979)        
  ypN Stage                                         0.648                      0.421                                         NI
   ypN1                           42.4%                                                                                        
   ypN2                           41.7%                                                                                        
  N/P LNs ratio                                    13.621                     \<0.001                                      \<0.001
   ≦2.33                          37.3%                                                                  Reference             
   \>2.33                         56.1%                                                             0.548(0.394--0.762)        
  No. of LNs                                       13.225                     \<0.001                                       0.013
   \<10                           32.4%                                                                  Reference             
   ≥10                            46.6%                                                             0.718(0.553--0.933)        

NI: not included in multivariate survival analysis.

N/P LNs ratio: The ratio of the number of negative lymph nodes to the number of metastatic lymph nodes.

^\*^P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.
